{"id":"W1851453522","doi":"10.1111/apt.13402","title":"Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases","year":2015,"lang":"en","type":"review","venue":"Alimentary Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials","funders":"UCB Pharma; Genentech; Vlaamse regering; Hellenic Society of Gastroenterology; Norgine; Agentschap voor Innovatie door Wetenschap en Technologie; Fonds Wetenschappelijk Onderzoek; Celltrion; European Crohn's and Colitis Organisation; National Institute for Health and Care Research; Janssen Biotech; Teva Pharmaceutical Industries; Celgene; Pfizer; Biogen; Ablynx; Gilead Sciences; Amgen; ActoGeniX; Sanofi; Tillotts Pharma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ironwood Pharmaceuticals, Incorporated","keywords":"Biosimilar; Medicine; Infliximab; Adalimumab; Inflammatory bowel disease; Ulcerative colitis; Bioequivalence; Rheumatoid arthritis; Pharmacokinetics; Drug; Pharmacology; Crohn's disease; Pharmacodynamics; Ankylosing spondylitis; Internal medicine; Immunology; Tumor necrosis factor alpha; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001353188,0.0009725022,0.002050315,0.004305465,0.0003709435,0.002096617,0.001065135,0.002507484,0.007938317],"category_scores_gemma":[0.003596239,0.0002550412,0.001027015,0.005844029,0.0004950187,0.00195576,0.0009348036,0.001898245,0.00249101],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001014289,"about_ca_system_score_gemma":0.00250156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000887596,"about_ca_topic_score_gemma":0.001132882,"domain_scores_codex":[0.9988394,0.0002618603,0.0003001833,0.0001388034,0.0003880335,0.00007169014],"domain_scores_gemma":[0.9972935,0.001393929,0.000516663,0.000045507,0.0005760807,0.0001742282],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002437656,0.0001039565,0.0003107616,0.1099871,0.0003688549,0.0005023186,0.0001813901,0.0003816181,0.001534018,0.002627185,0.1102511,0.7735079],"study_design_scores_gemma":[0.00006445962,0.0001671611,0.001453023,0.0241237,0.0004990427,0.002492651,0.000125454,0.0001008299,0.0003987418,0.00130427,0.9692432,0.00002735884],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001295102,0.9967235,0.000080761,0.0006924974,0.001387938,0.00001198586,0.00004258237,0.000005481147,0.0009257961],"genre_scores_gemma":[0.0009631885,0.9955183,0.00016113,0.0008007792,0.001990444,0.00001276717,0.00006763286,0.000002132869,0.000483516],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007938317,"threshold_uncertainty_score":0.02655637,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08557301642064606,"score_gpt":0.4069166715807467,"score_spread":0.3213436551601006,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}